<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00492167</url>
  </required_header>
  <id_info>
    <org_study_id>05-073</org_study_id>
    <secondary_id>MSKCC-05073</secondary_id>
    <nct_id>NCT00492167</nct_id>
  </id_info>
  <brief_title>Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma</brief_title>
  <official_title>Phase I Study of Oral Yeast β-Glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients With Metastatic Neuroblastoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Beta-glucan may stimulate the immune system and stop tumor cells from growing.&#xD;
      Monoclonal antibodies, such as 3F8, can block tumor growth in different ways. Some block the&#xD;
      ability of tumor cells to grow and spread. Others find tumor cells and help kill them or&#xD;
      carry tumor-killing substances to them. Giving beta-glucan together with monoclonal antibody&#xD;
      3F8 may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of beta-glucan when&#xD;
      given together with monoclonal antibody 3F8 in treating patients with metastatic&#xD;
      neuroblastoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the clinical toxicity of beta-glucan in combination with monoclonal antibody&#xD;
           3F8 in patients with metastatic neuroblastoma.&#xD;
&#xD;
        -  Evaluate the biologic effects of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of beta-glucan.&#xD;
&#xD;
      Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV&#xD;
      over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses&#xD;
      in the absence of disease progression or unacceptable toxicity and with a human antimouse&#xD;
      antibody (HAMA) titer &lt; 1,000 U/mL.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Patients undergo urine, bone marrow, and blood sample collection periodically for biological&#xD;
      studies. Samples are analyzed for antibody-dependent cellular cytotoxicity,&#xD;
      complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2005</start_date>
  <completion_date type="Actual">March 4, 2022</completion_date>
  <primary_completion_date type="Actual">March 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Beta-Glucan and Monoclonal Antibody 3F8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a dose-escalation study of beta-glucan. Patients receive oral beta-glucan once daily on days -4 to 12 and monoclonal antibody 3F8 IV over 30-90 minutes on days 1-5 and 8-12. Treatment repeats every 4 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity and with a human antimouse antibody (HAMA) titer &lt; 1,000 U/mL.&#xD;
Cohorts of 3-6 patients receive escalating doses of beta-glucan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
Patients undergo urine, bone marrow, and blood sample collection periodically for biological studies. Samples are analyzed for antibody-dependent cellular cytotoxicity, complement-mediated cytotoxicity, and serum HAMA response via immunohistochemistry.&#xD;
After completion of study treatment, patients are followed periodica</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>beta-glucan</intervention_name>
    <arm_group_label>Beta-Glucan and Monoclonal Antibody 3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody 3F8</intervention_name>
    <arm_group_label>Beta-Glucan and Monoclonal Antibody 3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <arm_group_label>Beta-Glucan and Monoclonal Antibody 3F8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>Beta-Glucan and Monoclonal Antibody 3F8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of neuroblastoma by 1 of the following methods:&#xD;
&#xD;
               -  Histopathology&#xD;
&#xD;
               -  Bone marrow involvement AND elevated urinary catecholamines&#xD;
&#xD;
          -  High-risk disease, defined by 1 of the following:&#xD;
&#xD;
               -  Stage 4 disease with MYCN amplification (any age) or without MYCN amplification&#xD;
                  (&gt; 18 months of age)&#xD;
&#xD;
               -  MYCN-amplified stage 3 disease (unresectable and any age)&#xD;
&#xD;
               -  MYCN-amplified stage 4S disease&#xD;
&#xD;
          -  Metastatic disease&#xD;
&#xD;
          -  Tumor progression or persistent disease (at metastatic or primary site) after&#xD;
             intensive conventional chemotherapy&#xD;
&#xD;
          -  Must have evaluable (microscopic marrow metastasis, elevated tumor markers, positive&#xD;
             MIBG or PET scans) or measurable (CT scan or MRI) disease documented after completion&#xD;
             of prior systemic therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Platelet count &gt; 25,000/mm^3&#xD;
&#xD;
          -  ANC &gt; 500/mm^3&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of allergy to mouse proteins, beta-glucan, mushrooms, or yeast&#xD;
&#xD;
          -  No active life-threatening infections&#xD;
&#xD;
          -  No severe major organ toxicity&#xD;
&#xD;
               -  Concurrent toxicity must be ≤ grade 2 except for the following, which may be&#xD;
                  grade 3:&#xD;
&#xD;
                    -  Myelosuppression&#xD;
&#xD;
                    -  Hearing loss&#xD;
&#xD;
                    -  Alopecia&#xD;
&#xD;
                    -  Anorexia&#xD;
&#xD;
                    -  Nausea&#xD;
&#xD;
                    -  Hyperbilirubinemia from TPN&#xD;
&#xD;
                    -  Anxiety&#xD;
&#xD;
                    -  Hypomagnesemia&#xD;
&#xD;
          -  No prior HAMA titer &gt; 1,000 U/mL by ELISA&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent supplemental beta-glucan in food (e.g., bran cereals or mushrooms) or as&#xD;
             complementary medicine&#xD;
&#xD;
          -  No other concurrent systemic anticancer medications (e.g., hormonal agents,&#xD;
             chemotherapy, investigational agents, or immunotherapy)&#xD;
&#xD;
               -  Concurrent isotretinoin allowed after the second course of study treatment is&#xD;
                  completed or if the patient develops human antimouse antibody (HAMA)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shakeel Modak, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian H. Kushner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2007</study_first_posted>
  <last_update_submitted>March 4, 2022</last_update_submitted>
  <last_update_submitted_qc>March 4, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>regional neuroblastoma</keyword>
  <keyword>stage 4S neuroblastoma</keyword>
  <keyword>disseminated neuroblastoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

